Genome-wide identification of direct target genes implicates estrogen-related receptor alpha as a determinant of breast cancer heterogeneity.

Estrogen-related receptor alpha (ERRalpha) is an orphan nuclear receptor, the expression of which correlates with negative prognosis in breast cancer. ERRalpha shares functional features with the estrogen receptor alpha (ERalpha) and its activity is modulated by the ERBB2 signaling pathway. Using genome-wide binding sites location analyses in ERalpha-positive and ERalpha-negative breast cancer cell lines, we show that ERRalpha and ERalpha display strict binding site specificity and maintain independent mechanisms of transcriptional activation. Nonetheless, ERRalpha and ERalpha coregulate a small subset of common target genes via binding either to a dual-specificity binding site or to distinct cognate binding sites located within the extended promoter region of the gene. Although ERRalpha signaling in breast cancer cells is mostly independent of ERalpha, the small fraction of common ERRalpha/ERalpha targets comprises genes with high relevance to breast tumor biology, including genes located within the ERBB2 amplicon and GATA3. Finally, unsupervised hierarchical clustering based on the expression profiling of ERRalpha direct target genes in human breast tumors revealed four main clusters that recapitulate established tumor subtypes. Taken together, the identification and functional characterization of the ERRalpha transcriptional network implicate ERRalpha signaling as a determinant of breast cancer heterogeneity.

[1]  K. Pienta,et al.  Global gene expression profiling of circulating tumor cells. , 2005, Cancer research.

[2]  Zhiping Zhang,et al.  Estrogen receptor α and estrogen receptor-related receptor α1 compete for binding and coactivator , 2001, Molecular and Cellular Endocrinology.

[3]  J. Yates,et al.  Adaptation of energy metabolism in breast cancer brain metastases. , 2007, Cancer research.

[4]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Y. Kamei,et al.  PPARγ coactivator 1β/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Simak Ali,et al.  Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen , 2008, Nature.

[7]  H. Wilkinson,et al.  Estrogen-related receptor-α antagonist inhibits both estrogen receptor–positive and estrogen receptor–negative breast tumor growth in mouse xenografts , 2009, Molecular Cancer Therapeutics.

[8]  F. Stossi,et al.  Whole-Genome Cartography of Estrogen Receptor α Binding Sites , 2007, PLoS genetics.

[9]  Christian A. Rees,et al.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[11]  E. Ariazi,et al.  Estrogen-related Receptor α1 Actively Antagonizes Estrogen Receptor-regulated Transcription in MCF-7 Mammary Cells* , 2002, The Journal of Biological Chemistry.

[12]  Clifford A. Meyer,et al.  Genome-wide analysis of estrogen receptor binding sites , 2006, Nature Genetics.

[13]  I. Fichtner,et al.  Relation of oestradiol-mediated growth stimulation with the expression of c-erbB-2 protein in xenotransplanted oestradiol-receptor-positive and -negative breast carcinomas , 2005, Journal of Cancer Research and Clinical Oncology.

[14]  A. Biankin,et al.  The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome , 2008, Breast Cancer Research.

[15]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Clifford A. Meyer,et al.  Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1 , 2005, Cell.

[17]  Céline Lefebvre,et al.  From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Simak Ali,et al.  Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.

[19]  E. Ariazi,et al.  Estrogen-Related Receptor α1 Transcriptional Activities Are Regulated in Part via the ErbB2/HER2 Signaling Pathway , 2007, Molecular Cancer Research.

[20]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[21]  P S Meltzer,et al.  Endogenously expressed estrogen receptor and coactivator AIB1 interact in MCF-7 human breast cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[23]  V. Giguère,et al.  Nuclear receptor location analyses in mammalian genomes: from gene regulation to regulatory networks. , 2008, Molecular endocrinology.

[24]  Mieke Timmermans,et al.  Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  V. Giguère.  Transcriptional control of energy homeostasis by the estrogen-related receptors. , 2008, Endocrine reviews.

[26]  Joshy George,et al.  Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. , 2006, Cancer research.

[27]  J. Winstanley,et al.  Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. , 2006, Cancer research.

[28]  J. Marks,et al.  Age-Specific Differences in Oncogenic Pathway Deregulation Seen in Human Breast Tumors , 2008, PloS one.

[29]  Céline Lefebvre,et al.  Location analysis of estrogen receptor target promoters reveals that FOXA 1 defines a domain of the estrogen response , 2005 .

[30]  M. Polymeropoulos,et al.  Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer. , 2003, Cancer research.

[31]  V. Giguère.  To ERR in the estrogen pathway , 2002, Trends in Endocrinology & Metabolism.

[32]  H. Aburatani,et al.  Transforming growth factor-beta promotes survival of mammary carcinoma cells through induction of antiapoptotic transcription factor DEC1. , 2007, Cancer research.

[33]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[34]  E. Ariazi,et al.  Estrogen-related Receptor α and Estrogen-related Receptor γ Associate with Unfavorable and Favorable Biomarkers, Respectively, in Human Breast Cancer , 2002 .

[35]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[36]  V. Giguère,et al.  Epidermal Growth Factor–Induced Signaling in Breast Cancer Cells Results in Selective Target Gene Activation by Orphan Nuclear Receptor Estrogen-Related Receptor α , 2005 .

[37]  W. Bremner,et al.  Advances in male contraception. , 2008, Endocrine reviews.

[38]  R. Evans,et al.  Identification of a new class of steroid hormone receptors , 1988, Nature.

[39]  W. Stevens,et al.  Identification of a selective inverse agonist for the orphan nuclear receptor estrogen-related receptor alpha. , 2004, Journal of medicinal chemistry.

[40]  J. Gustafsson,et al.  Transcriptional targets shared by estrogen receptor‐related receptors (ERRs) and estrogen receptor (ER) α, but not by ERβ , 1999 .

[41]  M. Jahanzeb.  Adjuvant trastuzumab therapy for HER2-positive breast cancer. , 2008, Clinical breast cancer.

[42]  V. Giguère,et al.  A Polymorphic Autoregulatory Hormone Response Element in the Human Estrogen-related Receptor α (ERRα) Promoter Dictates Peroxisome Proliferator-activated Receptor γ Coactivator-1α Control of ERRα Expression* , 2004, Journal of Biological Chemistry.

[43]  Thies Schroeder,et al.  Estrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer. , 2008, Cancer research.

[44]  Carlos Caldas,et al.  Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis , 2007, Nature Reviews Cancer.

[45]  Takashi Suzuki,et al.  Estrogen-Related Receptor α in Human Breast Carcinoma as a Potent Prognostic Factor , 2004, Cancer Research.

[46]  Jun S. Liu,et al.  An algorithm for finding protein–DNA binding sites with applications to chromatin-immunoprecipitation microarray experiments , 2002, Nature Biotechnology.

[47]  V. Giguère,et al.  Functional genomics identifies a mechanism for estrogen activation of the retinoic acid receptor alpha1 gene in breast cancer cells. , 2005, Molecular endocrinology.

[48]  Brian J. Wilson,et al.  Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway , 2008, Molecular Cancer.

[49]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[50]  A. Sboner,et al.  UbcH10 is overexpressed in malignant breast carcinomas. , 2007, European journal of cancer.

[51]  R. Spang,et al.  Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.